You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Find more safety information in the supplementary patient handouts:

How to Safely Take Your Oral Anti-Cancer Medication

Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.

Displaying Drugs List

179 Items
Other Name(s): Verzenio™
Jul 2020
Other Name(s): Zytiga®
Funding:
Exceptional Access Program
  • abiraterone - Metastatic castrate-resistant prostate cancer, according to specific criteria
Feb 2022
Other Name(s): Calquence®
Funding:
Exceptional Access Program
  • acalabrutinib - For the treatment of adult patients with chronic lymphocytic leukemia (CLL), according to clinical criteria
Feb 2022
Other Name(s): Giotrif®
Funding:
Exceptional Access Program
  • AFAtinib - For first-line monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
Jun 2022
Other Name(s): Proleukin® (interleukin-2)
Funding:
New Drug Funding Program
  • Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
Jun 2019
Other Name(s): Alecensaro™
Funding:
Exceptional Access Program
  • Treatment of non-small cell lung cancer according to clinical criteria
May 2022
Other Name(s): MabCampath®
Sep 2019
Other Name(s): Piqray®
Mar 2022
Other Name(s): AMSA P D® (Erfa)
Sep 2011
Other Name(s): Agrylin® (Shire Pharma)
Jul 2017
Other Name(s): Arimidex®
Funding:
ODB - General Benefit
  • anastrozole
Sep 2021
Other Name(s): Erleada®
Funding:
Exceptional Access Program
  • apalutamide - For the treatment of non-metastatic castration resistant prostate cancer (nmCRPC) according to clinical criteria
  • For the treatment of metastatic castration sensitive prostate cancer (mCSPC), according to clinical criteria
Feb 2022

Pages